Operation TrialBlazer: If Drug Development Picks Up Speed, Judgment Is the Constraint That Remains

Operation TrialBlazer aims to reduce administrative delay in early drug development. If it does, the pace will be set by something harder to regulate: early go/no-go judgment calls.

In June 2026, the Department of Health and Human Services issued Operation TrialBlazer, a department-wide roadmap to speed clinical research in order to increase clinical trials in the United States. The roadmap notes that China's share of Phase 1 trials surpassed that of the U.S. for the first time in 2021, and that by 2024 China had overtaken the U.S. in total registered trials, holding about 39% of the global total.^1,2

Even as TrialBlazer aims to remove delay, it may expose a constraint that speed cannot remove. The pace of early development is still set by how effectively a sponsor can make early go/no-go decisions.

Much of Operation TrialBlazer is not yet in effect

While the headline structural reforms are not yet in place, the FDA has consolidated early-stage expectations on a new Phase 1 IND Navigator webpage, updated its guidance on chemistry, manufacturing and controls, and opened a Phase 1 Contact Center for early-phase regulatory questions. The Expedited-IND Acceleration Pilot, which would let vetted partners help prepare and review IND components before submission, exists so far as a request for information. A single-IRB requirement for multi-site studies is described as potential rulemaking. And the shift toward risk-based nonclinical testing and New Approach Methodologies, which can in defined cases reduce or replace animal studies, is a direction set out in draft guidance, not a finished rule.³

The reforms move value from execution to judgment

Nearly every efficiency reform in the roadmap removes a category of work that used to be mandatory. HHS estimates that about 45% of protocol amendments are somewhat or completely avoidable, and that simplifying protocols could cut the cost of bringing a drug to market by up to 22%; officials believe phase-appropriate requirements could save sponsors six to 12 months in early development. Duplicative reviews, animal studies of limited value, months of conservative over-submission: the throughline is the removal of work that added time without adding safety.

When a pathway is slow and ambiguous, much of the advantage lives in execution: running the studies and absorbing the redundancy. When the pathway is faster and clearer, the advantage shifts to the decision points and the judgment tasks. The roadmap itself observes that smaller sponsors are often least equipped to handle this shift alone.

The necessary judgment must be exercised earlier than teams might think. In the view of Colin G. Miller, clinical trials imaging scientist, CEO of The Bracken Group and co-editor of "Medical Imaging in Clinical Trials" (Springer, 2014), most of the delay in a development program is decided long before it becomes visible, usually before the first patient is enrolled. Programs rarely go slow because work stops; they go slow because a question that was underspecified at the design stage resurfaces downstream, where it costs far more to answer. In one late-stage oncology program Miller reviewed, the variability in the imaging assessments had little to do with the drug and a great deal to do with how the images were acquired: across different sites, scanners, timing and reader conventions. The remedy was not more data but better-specified data. That is the discipline the roadmap creates room for but cannot supply: knowing when you know enough to make the next irreversible decision, and reverse-engineering study design from that decision point.

Where evidentiary weight now falls: imaging and radioligand therapy

As the FDA leans on New Approach Methodologies to lighten the animal-testing leg of the evidence base, more of the weight falls on human data, and in early oncology a good deal of that human data is imaging. An imaging endpoint that is well specified, consistently acquired across sites, and read to a defensible standard can carry real evidentiary weight; one that is loosely specified cannot, and no amount of speed elsewhere compensates. The reforms do not rewrite the rules of imaging. They raise the weight those rules have to hold.

Radioligand therapy is the sharpest illustration. The roadmap points to it, alongside cell, gene and stem-cell therapies, as a cutting-edge modality where China's flexible, investigator-initiated approach is drawing investment away from the United States. However, it is also a field where the scan often decides eligibility rather than describing disease: patient selection for a prostate-specific membrane antigen (PSMA)-targeted therapy such as Pluvicto is made by PSMA PET, so the image determines who is treated at all.⁴ Give such a field more speed and flexibility, Miller notes, and both the value of getting the imaging right and the cost of getting it wrong go up. Faster selection helps only if the selection is correct.

That is the trap inside the opportunity. Removing avoidable delay is a real saving. Relaxing the core-lab discipline that keeps an imaging endpoint consistent and auditable is not; it is a cost deferred to the moment a reviewer asks how a read was produced and whether it would hold up a second time. More speed and more artificial intelligence tooling do not remove the need for consistent, regulator-defensible reads. They sharpen it, because each new tool is another place inconsistency can enter unnoticed. The skill is to apply the speed to the redundant work and keep the rigor where the evidence is made.

What sponsors should do now

So what should a sponsor do now? The near-term playbook follows from the distinctions in the roadmap itself:

If Operation TrialBlazer is successful in negating administrative delay, the pace of development will then be set by what was always underneath it: how well, and how early, teams decide to move forward.

The real question may not be whether the TrialBlazer roadmap makes trials faster, but how sponsors will adapt to the early, high-stakes decisions more speed can expose.